Clinical Trials Sponsored by Jiangsu Kanion Pharmaceutical Co.,Ltd

Total 4680 results

Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Pain

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Non-Small-Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Advanced Hepatocellular Carcinoma

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Metastatic Pancreatic Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Breast Cancer | Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics, Safety and Efficacy of HR020602 Injection in Children Undergoing General Anesthesia

Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)

China
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

COVID-19

Russian Federation, Nepal
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A SHR0302 BA Study on Healthy Subjects

Autoimmune Diseases

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia

Mixed Hyperlipidemia | Non-familial Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Hyperuricemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Bioequivalence Study of Hetrombopag in Healthy Subjects

Sever Aplastic Anaemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Drug-Drug Interaction Study Between Henagliflozin Proline and Hydrochlorothiazide

Diabetes in Adults

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 in Patients With Advanced Tumors

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Gout

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

AML | MDS

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients

Osteoporosis

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN046 in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma | Advanced Solid Tumors

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Jiangsu Rec-Biotechnology Co., Ltd.

Completed

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)

COVID-19

United Arab Emirates
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Breast Cancer | Solid Tumor | Gastrointestinal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Psoriatic Arthritis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

Hypercholesterolemia and Hyperlipidemia

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

B-cell Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Advanced Esophageal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

Hyperlipidemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China

3

Subscribe